Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Life after Merck: What Idenix's Renaud did next

This article was originally published in Scrip

Executive Summary

In June, Merck & Co announced it was bolstering its position in the highly competitive hepatitis C arena with the acquisition of Idenix Pharmaceuticals for $3.85bn (scripintelligence.com, 9 June 2014). The transaction closed in August.

You may also be interested in...



Dyne Launches With $50m For Antibody Conjugates That Deliver Oligonucleotides To Muscles

The start-up incubated by Atlas Venture is focused on the delivery of nucleic acids and other molecules to skeletal, cardiac and smooth muscles. The Series A round will allow Dyne to take its lead program for myotonic dystrophy type 1 (DM1) into the clinic.

Early Stage Candidates Carving Out New Routes In Cystic Fibrosis

Scrip spoke to two companies from a fresh wave of innovators that are approaching drug development for cystic fibrosis from a new angle.

Vertex Set To Dominate Cystic Fibrosis Market For The Next Decade

Vertex is set to reap huge benefits from its triple combination program for cystic fibrosis over the next 10 years, potentially becoming the biggest selling drug in this disease, according to a new report from Datamonitor Healthcare.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC027169

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel